MedTrace Logo

Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

NCT00808392 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 916

Last updated 2011-12-29

No results posted yet for this study

Summary

This study will investigate safety and immunogenicity of a monovalent conjugated vaccine against Haemophilus influenzae type b in healthy children aged 2 to 4 months in China.

Conditions

  • Haemophilus Influenzae Type b

Interventions

BIOLOGICAL

Haemophilus influenzae type b vaccine

3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine

BIOLOGICAL

Commercial Haemophilus influenzae type b vaccine

3 doses one month apart of Haemophilus influenzae type b vaccine.

Sponsors & Collaborators

  • Novartis Vaccines

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
4 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00808392 on ClinicalTrials.gov